It is established that carriers of BRCA1 and BRCA2 mutations benefit from magnetic resonance imaging (MRI) of the breast, preventive mastectomy, prophylactic oophorectomy, and women with breast or ovarian cancer and a BRCA1/2 mutation benefit from individualized chemotherapy using platins and PARP1 inhibitors [47,48,49,50]. Here, PARP1 is linked to ovarian carcinoma.